We studied 677 cases with idiopathic sudden sensorineural hearing loss (ISSNHL) treated with at least intravenous batroxobin, oral betamethasone, and hyperbaric oxygen therapy. The 677 patients received at least intravenous batroxobin from 2005 to 2008.
Overall “cure” was 30.7%, 44.2% for Grade 1, 34.4% for Grade 2, 32.2% for Grade 3, and 8.1% for Grade 4. Within the twelve days between onset and treatment start, “cure” was 38.2%. Hearing loss severity and the duration both significantly influenced hearing recovery.
